Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer

BACKGROUND. Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity. The tolerability and efficacy of lower starting doses of sorafenib for DTC remain largely unstudied. METHODS. We retrospecti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Dadu, Ramona, Waguespack, Steven G., Sherman, Steven I., Hu, Mimi I., Busaidy, Naifa L., Jimenez, Camilo, Habra, Mohammed A., Ying, Anita K., Bassett, Roland L., Cabanillas, Maria E.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2014
Témata:
Endocrinology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012968/
https://ncbi.nlm.nih.gov/pubmed/24733667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0409
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky